16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Modulators of 14-3-3 Protein–Protein Interactions

      review-article
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Direct interactions between proteins are essential for the regulation of their functions in biological pathways. Targeting the complex network of protein–protein interactions (PPIs) has now been widely recognized as an attractive means to therapeutically intervene in disease states. Even though this is a challenging endeavor and PPIs have long been regarded as “undruggable” targets, the last two decades have seen an increasing number of successful examples of PPI modulators, resulting in growing interest in this field. PPI modulation requires novel approaches and the integrated efforts of multiple disciplines to be a fruitful strategy. This perspective focuses on the hub-protein 14-3-3, which has several hundred identified protein interaction partners, and is therefore involved in a wide range of cellular processes and diseases. Here, we aim to provide an integrated overview of the approaches explored for the modulation of 14-3-3 PPIs and review the examples resulting from these efforts in both inhibiting and stabilizing specific 14-3-3 protein complexes by small molecules, peptide mimetics, and natural products.

          Related collections

          Most cited references131

          • Record: found
          • Abstract: found
          • Article: not found

          The structural basis for 14-3-3:phosphopeptide binding specificity.

          The 14-3-3 family of proteins mediates signal transduction by binding to phosphoserine-containing proteins. Using phosphoserine-oriented peptide libraries to probe all mammalian and yeast 14-3-3s, we identified two different binding motifs, RSXpSXP and RXY/FXpSXP, present in nearly all known 14-3-3 binding proteins. The crystal structure of 14-3-3zeta complexed with the phosphoserine motif in polyoma middle-T was determined to 2.6 A resolution. The bound peptide is in an extended conformation, with a tight turn created by the pS +2 Pro in a cis conformation. Sites of peptide-protein interaction in the complex rationalize the peptide library results. Finally, we show that the 14-3-3 dimer binds tightly to single molecules containing tandem repeats of phosphoserine motifs, implicating bidentate association as a signaling mechanism with molecules such as Raf, BAD, and Cbl.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            An empirical framework for binary interactome mapping

            Several attempts have been made at systematically mapping protein-protein interaction, or “interactome” networks. However, it remains difficult to assess the quality and coverage of existing datasets. We describe a framework that uses an empirically-based approach to rigorously dissect quality parameters of currently available human interactome maps. Our results indicate that high-throughput yeast two-hybrid (HT-Y2H) interactions for human are superior in precision to literature-curated interactions supported by only a single publication, suggesting that HT-Y2H is suitable to map a significant portion of the human interactome. We estimate that the human interactome contains ~130,000 binary interactions, most of which remain to be mapped. Similar to estimates of DNA sequence data quality and genome size early in the human genome project, estimates of protein interaction data quality and interactome size are critical to establish the magnitude of the task of comprehensive human interactome mapping and to illuminate a path towards this goal.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm.

              Mammals express four highly conserved TEAD/TEF transcription factors that bind the same DNA sequence, but serve different functions during development. TEAD-2/TEF-4 protein purified from mouse cells was associated predominantly with a novel TEAD-binding domain at the amino terminus of YAP65, a powerful transcriptional coactivator. YAP65 interacted specifically with the carboxyl terminus of all four TEAD proteins. Both this interaction and sequence-specific DNA binding by TEAD were required for transcriptional activation in mouse cells. Expression of YAP in lymphocytic cells that normally do not support TEAD-dependent transcription (e.g., MPC11) resulted in up to 300-fold induction of TEAD activity. Conversely, TEAD overexpression squelched YAP activity. Therefore, the carboxy-terminal acidic activation domain in YAP is the transcriptional activation domain for TEAD transcription factors. However, whereas TEAD was concentrated in the nucleus, excess YAP65 accumulated in the cytoplasm as a complex with the cytoplasmic localization protein, 14-3-3. Because TEAD-dependent transcription was limited by YAP65, and YAP65 also binds Src/Yes protein tyrosine kinases, we propose that YAP65 regulates TEAD-dependent transcription in response to mitogenic signals.
                Bookmark

                Author and article information

                Journal
                J Med Chem
                J. Med. Chem
                jm
                jmcmar
                Journal of Medicinal Chemistry
                American Chemical Society
                0022-2623
                1520-4804
                02 October 2017
                10 May 2018
                : 61
                : 9
                : 3755-3778
                Affiliations
                []Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems (ICMS), Eindhoven University of Technology , P.O. Box 513, 5600 MB, Eindhoven, The Netherlands
                []Department of Biotechnology, Chemistry and Pharmacy, University of Siena , Via Aldo Moro 2, 53100 Siena, Italy
                [§ ]Division of Cell and Developmental Biology, School of Life Sciences, University of Dundee , Dundee DD1 4HN, United Kingdom
                []Department of Physical and Macromolecular Chemistry, Faculty of Science, Charles University , Prague 116 36, Czech Republic
                []Université deLille, CNRS, UMR 8576 , F 59 000 Lille, France
                [# ]School of Chemistry, University of Leeds , Woodhouse Lane, Leeds LS2 9JT, United Kingdom
                []Astbury Center For Structural Molecular Biology, University of Leeds , Woodhouse Lane, Leeds LS2 9JT, United Kingdom
                []Taros Chemicals GmbH & Co. KG , Dortmund 44227, Germany
                []Lead Discovery Center GmbH , Dortmund 44227, Germany
                []UCB Celltech , 216 Bath Road, Slough SL1 3WE, United Kingdom
                []GlaxoSmithKline , Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, United Kingdom
                [$ ]Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development Biotech Unit, AstraZeneca Gothenburg , Pepparedsleden 1, SE-431 83 Mölndal, Sweden
                [@ ]Department of Chemistry, University of Duisburg-Essen , Universitätstraße 7, 45141 Essen, Germany
                Author notes
                [* ]E-mail: c.ottmann@ 123456tue.nl . Tel.: +31 40-247 2835.
                Article
                10.1021/acs.jmedchem.7b00574
                5949722
                28968506
                c0f4e19c-674e-475e-a8a5-f4e70c96a87b
                Copyright © 2017 American Chemical Society

                This is an open access article published under a Creative Commons Non-Commercial No Derivative Works (CC-BY-NC-ND) Attribution License, which permits copying and redistribution of the article, and creation of adaptations, all for non-commercial purposes.

                History
                : 14 April 2017
                Categories
                Perspective
                Custom metadata
                jm7b00574
                jm-2017-00574r

                Pharmaceutical chemistry
                Pharmaceutical chemistry

                Comments

                Comment on this article